skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In-depth news and analysis

Generics_Bulletin2

How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.

How it works

A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.

Analysis and opinion covers key topic areas such as:

  • Regulatory and compliance changes
  • Legal and legislations advances
  • Competitive developments
  • Merger and acquisition activities
  • New product launches
  • Marketing challenges
  • Advertising strategies, and more.

What's included

Pharma Intelligence: latest

  • Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Generics Bulletin

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    Donald Trump

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

  • In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...

    Coronavirus: Keep up to date with Breaking News and Insight

    Coronavirus_Cover

    Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.

    Topic Coronavirus

  • Generics Bulletin

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Corona_Invivo

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

  • Generics Bulletin

    Celltrion Pledges Efforts on Coronavirus Antibody And Kit

    Coronavirus

    Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

    Topic Coronavirus

  • Generics Bulletin

    Green Lanes Will Help EU Fight Coronavirus

    Coronavirus Europe

    Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

    Topic Coronavirus

  • Generics Bulletin

    European Coronavirus Planning Requires ‘Structured Dialog’

    Coronavirus

    European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

    Topic Coronavirus

  • Generics Bulletin

    Sun Finds US ‘Challenging’

    Flags_USA_India

    Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

    Topic Deal trends

  • Generics Bulletin

    Who’s Hired? Sandoz Germany Seeks A New Country Head

    Whos_Hired_Sandoz_Germany

    While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

    Topic Business Strategies

  • Generics Bulletin

    Celltrion Sets Out Strategy For China

    Celltrion_Sets_Out_Strategy_For_China

    Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

  • Generics Bulletin

    Coherus Is Confident After US Ranibizumab Filing

    Coherus_Is_Confident_After_US

    Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

    Topic Biosimilars Deal trends

  • Generics Bulletin

    California Plans To Create Own Generics Label

    California_Plans_To_Create_Own_Generics_Label

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

  • Generics Bulletin

    Biocon Biologics Gets True North Investment

    Biocon_Biologics_Gets_True_North_Investment

    Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

    Topic Deal trends Strategy

  • Generics Bulletin

    Alberta Is Second Canadian Province To Switch To Biosimilars

    Alberta_Is_Second_Canadian_Province_To_Switch_1

    Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

  • Generics Bulletin

    Global Industry Hails Bioequivalence Progress

    Article

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Meet the team

Management

Mike Ward

Management, Head of Content

UK

Mike Ward

Mike specializes in

  • Biopharma Pipeline Strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Companies

+36 year(s) experience

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market Intelligence

+22 year(s) experience

Editor

Andrea Charles

Editor, Editor, Custom Content

UK

Andrea Charles

Andrea specializes in

  • Biosimilars
  • Biotech
  • Commercial Strategy
  • Generics
  • Clinical Trials

+17 year(s) experience

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: